Get the Stockscreener App
0.9104
42.63%
0.2721
Kala Bio Inc stock is traded at $0.9104, with a volume of 30.65M.
It is up +42.63% in the last 24 hours and up +14.39% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$0.6383
Open:
$0.797
24h Volume:
30.65M
Relative Volume:
19.83
Market Cap:
$6.39M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.073
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
+43.82%
1M Performance:
+14.39%
6M Performance:
-77.47%
1Y Performance:
-85.97%
1-Day Range:
$0.7013
$1.14
1-Week Range:
$0.6076
$1.14
52-Week Range:
$0.6076
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.9104 | 5.24M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-29-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-08-25 | Initiated | Mizuho | Outperform |
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
What Sparked KALA BIO's Nearly 38% Surge Overnight? - Benzinga
Kala Bio IncOn Nov 21, board terminated without cause the employment of Mary Reumuth, company's chief financial officer - MarketScreener
Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Collapse - Stocktwits
KALA BIO, Inc. announced that it expects to receive $6 million in funding - MarketScreener
KALA BIO Inc. (KALA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What drives KALA BIO Inc stock priceMarket Rumors and News & Minimal Investment Portfolio Growth - earlytimes.in
Real time scanner hits for KALA BIO Inc. explainedEarnings Growth Summary & Weekly High Conviction Ideas - newser.com
KALA BIO: Q3 Earnings Snapshot - Connecticut Post
Is KALA BIO Inc. stock vulnerable to regulatory risksWeekly Trend Summary & Consistent Growth Equity Picks - newser.com
Chart based exit strategy for KALA BIO Inc.Trade Risk Assessment & Proven Capital Preservation Methods - newser.com
Will KALA BIO Inc. stock outperform international peersWeekly Investment Report & Weekly High Conviction Ideas - newser.com
Risk vs reward if holding onto KALA BIO Inc.Portfolio Update Summary & Free Risk Controlled Daily Trade Plans - newser.com
Is KALA BIO Inc. stock trading at a premium valuation2025 Volume Leaders & Free Real-Time Volume Trigger Notifications - newser.com
KALA BIO, Inc. SEC 10-Q Report - TradingView
[10-Q] KALA BIO, Inc. Quarterly Earnings Report | KALA SEC FilingForm 10-Q - Stock Titan
Applying Elliott Wave Theory to KALA BIO Inc.Trade Exit Summary & Weekly High Return Forecasts - newser.com
Best data tools to analyze KALA BIO Inc. stockPortfolio Performance Report & Accurate Buy Signal Alerts - newser.com
Is KALA BIO Inc. stock supported by innovation pipelineWeekly Trend Report & Fast Gain Stock Tips - newser.com
Is KALA BIO Inc. stock a contrarian buyGap Down & Free High Accuracy Swing Entry Alerts - newser.com
Real time alert setup for KALA BIO Inc. performanceJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
What to do if you’re stuck in KALA BIO Inc.Trade Signal Summary & Free Community Supported Trade Ideas - newser.com
Will KALA BIO Inc. stock outperform value stocksJuly 2025 Recap & AI Enhanced Trading Alerts - newser.com
Kala Pharmaceuticals Delays Quarterly Report Filing - MSN
Detecting support and resistance levels for KALA BIO Inc.2025 Geopolitical Influence & High Accuracy Investment Signals - newser.com
[NT 10-Q] KALA BIO, Inc. SEC Filing - Stock Titan
Return on assets % of KALA BIO, Inc. – HAM:27F0 - TradingView
Long term debt to total assets ratio of KALA BIO, Inc. – HAM:27F0 - TradingView
Is KALA BIO Inc. stock a good choice for value investorsOptions Play & Long-Term Safe Investment Ideas - Fundação Cultural do Pará
Kala Pharmaceuticals Faces Nasdaq Compliance Challenge - MSN
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 22 '25 |
Sale |
0.83 |
32,230 |
26,751 |
29,873 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 23 '25 |
Sale |
0.82 |
967 |
793 |
28,906 |
| Bazemore Todd | Director |
Oct 22 '25 |
Sale |
0.83 |
47,768 |
39,647 |
35,932 |
| Brazzell Romulus K | SEE REMARKS |
Oct 22 '25 |
Sale |
0.83 |
46,748 |
38,801 |
35,952 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
Oct 22 '25 |
Sale |
0.83 |
20,806 |
17,269 |
41,760 |
0.76%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):